Skip to main content
SpringerLink
Log in

Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Olanzapine-induced weight gain is associated with atherosclerosis, hypertension, dyslipidemia, and diabetes. We synthesized a novel antipsychotic drug (PGW5) possessing an olanzapine moiety linked to sarcosine, a glycine transporter 1 inhibitor. In this study, we compared the metabolic effects of PGW5 and olanzapine in a female rat model of weight gain. Female rats were treated daily with oral olanzapine (4 mg/kg), PGW5 (25 mg/kg), or vehicle for 16 days. Behavioral tests were conducted on days 12–14. Biochemical analyses were performed at the end of the treatment. A significant increase in body weight was observed in the olanzapine-treated group, while the PGW5 group did not differ from the controls. The open field test showed hypo-locomotion in the olanzapine-treated animals as compared to PGW5 and control groups. A significant increase in hypothalamic protein expression of the neuropeptide Y5 receptor and a decrease in pro-opiomelanocortin messenger ribonucleic acid (mRNA) levels were detected following PGW5 treatment, but not after olanzapine administration. PGW5 appears to possess minor metabolic effects compared with the parent compound olanzapine. The differential modulation of brain peptides associated with appetite regulation is possibly involved in the attenuation of metabolic effects by PGW5.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Albaugh VL, Henry CR, Bello NT, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36–51

    Article  CAS  Google Scholar 

  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696

    CAS  PubMed  Google Scholar 

  • Breden EL, Liu MT, Dean SR (2009) Metabolic and cardiac side effects of second-generation antipsychotics: what every clinician should know. J Pharm Prac 22:478–488

    Article  Google Scholar 

  • Buhmann H, le Roux CW, Bueter M (2014) The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol 28:559–571

    Article  CAS  PubMed  Google Scholar 

  • Bymaster FP, Calligaro DO, Falcone JF, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  CAS  PubMed  Google Scholar 

  • Bymaster FP, Nelson DL, DeLapp NW, et al. (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107–122

    Article  CAS  PubMed  Google Scholar 

  • Coll AP, Farooqi IS, O’Rahilly S (2007) The hormonal control of food intake. Cell 129:251–256

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17:97–107

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Deng C, Weston-Green K, Huang XF (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain. Prog Neuro-Psychopharmacol Biol Psychiatry 34:1–4

    Article  Google Scholar 

  • Dietrich MO, Horvath TL (2009) Feeding signals and brain circuitry. Eur J Neurosci. 30:1688–1696

    Article  PubMed  Google Scholar 

  • Doslikova B, Garfield AS, Shaw J, et al. (2013) 5-HT2C receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated. J Neurosci. 33:9800–9804

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Freedman R (2005) The choice of antipsychotic drugs for schizophrenia. N Engl J Med 353:1286–1288

    Article  CAS  PubMed  Google Scholar 

  • Gameiro A, Reimann F, Habib AM, et al. (2005) The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol 569:761–772

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gardner DM, Baldessarini RJ, Waraich P (2005) Modern antipsychotic drugs: a critical overview. Synthese 172:1703–1711

    Google Scholar 

  • Gerald C, Walker MW, Criscione L, et al. (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168–171

    Article  CAS  PubMed  Google Scholar 

  • Ghahramanian Golzar M, Babri S, Ataie Z, Ebrahimi H, Mirzaie F, Mohaddes G (2013) NPY receptors blockade prevents anticonvulsant action of ghrelin in the hippocampus of rat. Dv Pharm Bull 3:265–271

    Google Scholar 

  • Gil-Ad I, Portnoy M, Tarasenko I, et al. (2014) A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. Eur Neuropsychopharmacol 24:425–436

    Article  CAS  PubMed  Google Scholar 

  • Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B (1999) Olanzapine: weight gain and therapeutic efficacy. J of Clin Psychopharm. 19:273–276

    Article  CAS  Google Scholar 

  • Holt RI (2006) Severe mental illness, antipsychotic drugs and the metabolic syndrome. British J Diabetes Vascular Disease 6:199–204

    Article  Google Scholar 

  • Hu Y, Bloomquist BT, Cornfield LJ, et al. (1996) Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem. 271:26315–26319

    Article  CAS  PubMed  Google Scholar 

  • Huszar D, Lynch CA, Fairchild-Huntress V, et al. (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131–141

    Article  CAS  PubMed  Google Scholar 

  • Jones B, Basson BR, Walker DJ, Crawford MK, Kinon BJ (2001) Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62:41–44

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med. 52:503–517

    Article  CAS  PubMed  Google Scholar 

  • Katz A, Meiri N (2006) Brain-derived neurotrophic factor is critically involved in thermal-experience-dependent developmental plasticity. J Neurosci. 26:3899–3907

    Article  CAS  PubMed  Google Scholar 

  • Larhammar D, Wraith A, Berglund MM, Holmberg SK, Lundell I (2001) Origins of the many NPY-family receptors in mammals. Peptides 22:295–307

    Article  CAS  PubMed  Google Scholar 

  • Leslie DL, Rosenheck RA (2002) From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 159:1534–1540

    Article  PubMed  Google Scholar 

  • Lian J, Huang XF, Pai N, Deng C (2014) Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS ONE 9:e104160

    Article  PubMed Central  PubMed  Google Scholar 

  • Meng H, Qingsheng Z, Chao D, Hongqin W, Jiamei L, Xu-Feng H (2014) Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 42:153–164

    Article  Google Scholar 

  • Mietlicki-Baase EG, Ortinski PI, Reiner DJ, et al. (2014) Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling. J Neurosci. 34:6985–6992

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Moller HJ (2000) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 1:204–214

    Article  CAS  PubMed  Google Scholar 

  • Mountjoy KG, Robbins LS, Mortrud MT, Cone RD (1992) The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248–1251

    Article  CAS  PubMed  Google Scholar 

  • Murashita M, Kusumi I, Inoue T, et al. (2005) Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30:106–110

    Article  CAS  PubMed  Google Scholar 

  • Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27–35

    Article  CAS  PubMed  Google Scholar 

  • Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 68:8–13

    Article  PubMed  Google Scholar 

  • Ottoni EB (2000) EthoLog 2.2: a tool for the transcription and timing of behavior observation sessions. Behavioral Research Methods Instruments and Computers 32:446–449

    Article  CAS  Google Scholar 

  • Pérez-Fernández J, Megías M, Pombal MA (2014) Cloning, phylogeny, and regional expression of a Y5 receptor mRNA in the brain of the sea lamprey. J Comp Neurol 522:1132–1154

    Article  PubMed  Google Scholar 

  • Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav. 75:133–140

    Article  CAS  PubMed  Google Scholar 

  • Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A (2013) Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology 226:615–622

    Article  CAS  PubMed  Google Scholar 

  • Qingsheng Z, Meng H, Chao D, Hongqin W, Jiamei L, Xu-Feng H (2014) Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. Inte Jl of Neuropsychopharm 17:807–818

    Article  Google Scholar 

  • Rolls ET (2005) Taste, olfactory, and food texture processing in the brain, and the control of food intake. Physiol Behav 85:45–56

    Article  CAS  PubMed  Google Scholar 

  • Sadock B, Sadock V (2007) Synopsis of Psychiatry, 1st edn. Lippincott, Philadelphia, Pa, USA

    Google Scholar 

  • Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671

    CAS  PubMed  Google Scholar 

  • Stefanidis A, Verty ANA, Allen AM, Owens NC, Cowley MA, Oldfield BJ (2009) The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 17:16–24

    Article  CAS  PubMed  Google Scholar 

  • Umbricht DS, Pollack S, Kane JM (1994) Clozapine and weight gain. J Cli Psychiatry. 55:157–160

    Google Scholar 

  • Van der Zwaal EM, Janhunen SK, la Fleur SE, Adan RA (2014) Modelling olanzapine-induced weight gain in rats. Int J Neuropsychopharmacol 17:169–186

    Article  PubMed  Google Scholar 

  • Zugno AI, Barcelos M, Ld O, et al. (2012) Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine. Rev Bras Psiquiatr 34:168–175

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the National Institute for Psychobiology in Israel.

Author information

Authors and Affiliations

  1. Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Michal Taler, Rea Globus, Abraham Weizman & Irit Gil-Ad

  2. Department of Psychology, Bar Ilan University, 52900, Ramat Gan, Israel

    Israel Vered, Liat Shbiro & Aron Weller

  3. Gonda (Goldschmied) Brain Research Center, Bar Ilan University, 52900, Ramat Gan, Israel

    Israel Vered, Liat Shbiro & Aron Weller

  4. Research Unit, Geha Mental Health Center, Petah Tikva, Israel

    Abraham Weizman

Authors
  1. Michal Taler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Israel Vered
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rea Globus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liat Shbiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abraham Weizman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aron Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Irit Gil-Ad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michal Taler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taler, M., Vered, I., Globus, R. et al. Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine. J Mol Neurosci 58, 66–73 (2016). https://doi.org/10.1007/s12031-015-0679-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-015-0679-2

Keywords

Search

Navigation